Yayınlar & Eserler

Yayın Ağı
Makaleler 13
Tümü (13)
SCI-E, SSCI, AHCI (10)
SCI-E, SSCI, AHCI, ESCI (13)
ESCI (3)
Scopus (12)
TRDizin (1)

1. The association between baseline IgE level and urticaria control at six months of omalizumab treatment in chronic urticaria

TUNCAY G., DAMADOĞLU E., KARAKAYA G., KALYONCU A. F.
European Annals of Allergy and Clinical Immunology , cilt.58, sa.3, ss.126-133, 2026 (ESCI, Scopus) Creative Commons License

2. Comparison of the characteristics of patients with chronic urticaria receiving standard-or high-dose omalizumab

TUNCAY G., DAMADOĞLU E., KARAKAYA G., KALYONCU A. F.
European Annals of Allergy and Clinical Immunology , cilt.58, sa.2, ss.69-76, 2026 (ESCI, Scopus) Creative Commons License

3. Comparison of the Efficacy of Omalizumab and Mepolizumab in Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease

CİHANBEYLERDEN M., TUNCAY G., KAYIKÇI H., DAMADOĞLU E., KARAKAYA G., KALYONCU A. F.
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY , cilt.185, ss.947-952, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

4. Successful desensitization in a patient with recurrent anaplastic oligodendroglioma presenting with procarbazine-mediated anaphylaxis

KAYIKÇI H., Can Bostan Ö., TUNCAY G., CİHANBEYLERDEN M., Tüccar Ç., DAMADOĞLU E., et al.
Journal of Oncology Pharmacy Practice , cilt.30, sa.5, ss.937-940, 2024 (SCI-Expanded, Scopus)

5. Efficacy and safety of hymenoptera venom immunotherapy

KAYIKÇI H., Bostan O. C., TUNCAY G., CİHANBEYLERDEN M., DAMADOĞLU E., KARAKAYA G., et al.
ALLERGY AND ASTHMA PROCEEDINGS , cilt.45, sa.4, ss.268-275, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

6. Urticaria exacerbations and adverse reactions in patients with chronic urticaria receiving COVID-19 vaccination: Results of the UCARE COVAC-CU study

Kocatürk E., Salameh P., Sarac E., Vera Ayala C. E., Thomsen S. F., Zuberbier T., et al.
Journal of Allergy and Clinical Immunology , cilt.152, sa.5, ss.1095-1106, 2023 (SCI-Expanded, Scopus)

7. Evaluation of disease control after SARS-CoV-2 infection or vaccination in patients with NSAID-exacerbated airway disease

CİHANBEYLERDEN M., CAN BOSTAN Ö., TUNCAY G., Safak C., DAMADOĞLU E., KARAKAYA G., et al.
Allergy and asthma proceedings , cilt.44, sa.4, 2023 (SCI-Expanded, Scopus)

8. SARS-CoV-2 vaccines are well tolerated in patients with mastocytosis

TUNCAY G., CAN BOSTAN Ö., DAMADOĞLU E., KARAKAYA G., KALYONCU A. F.
Annals of Allergy, Asthma and Immunology , cilt.128, sa.6, ss.733-734, 2022 (SCI-Expanded, Scopus) Creative Commons License

9. SARS-CoV-2 vaccines are well tolerated in patients with mastocytosis

TUNCAY G., CAN BOSTAN Ö., KARAKAYA G., KALYONCU A. F.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY , cilt.128, sa.6, ss.733-734, 2022 (SCI-Expanded, Scopus)

10. The association of timothy grass allergy and cat ownership on cat sensitization

CAN BOSTAN Ö., Cakmak M. E., Kaya S. B., TUNCAY G., DAMADOĞLU E., KARAKAYA G., et al.
ALLERGY AND ASTHMA PROCEEDINGS , cilt.43, sa.3, ss.220-225, 2022 (SCI-Expanded, Scopus)

11. The course of COVID-19 in patients with severe asthma receiving biological treatment

TUNCAY G., Cakmak M. E., CAN BOSTAN Ö., KAYA S. B., DAMADOĞLU E., KARAKAYA G., et al.
JOURNAL OF ASTHMA , cilt.59, sa.11, ss.2174-2180, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

12. Effect of COVID-19 on hereditary angioedema activity and quality of life

CAN BOSTAN Ö., TUNCAY G., DAMADOĞLU E., KARAKAYA G., KALYONCU A. F.
ALLERGY AND ASTHMA PROCEEDINGS , cilt.42, sa.5, ss.403-408, 2021 (SCI-Expanded, Scopus)

13. Mortality due to COVID-19 in a Patient with Severe Asthma Receiving Omalizumab Treatment: A Case Report

Cakmak M. E., KAYA S. B., CAN BOSTAN Ö., TUNCAY G., DAMADOĞLU E., KARAKAYA G., et al.
ASTIM ALLERJI IMMUNOLOJI , cilt.18, ss.27-29, 2020 (ESCI, TRDizin) Sürdürülebilir Kalkınma
Metrikler

Yayın

13

Yayın (WoS)

13

Yayın (Scopus)

12

Atıf (WoS)

17

H-İndeks (WoS)

3

Atıf (Scopus)

54

H-İndeks (Scopus)

3

Açık Erişim

3
BM Sürdürülebilir Kalkınma Amaçları
SDG 3: AMAÇ 3: SAĞLIKLI BİREYLER